Research Growth and AI Licensing Drive Wiley’s Third Quarter 2025 Results
Wiley (NYSE: WLY) reported strong Q3 2025 results with notable improvements in profitability despite revenue challenges. Third quarter revenue was $405 million, down from $461 million due to divested businesses, but adjusted revenue grew 1.2% at constant currency. Research segment showed robust performance with 5.2% growth.
Q3 Operating Income reached $52 million compared to ($46 million) prior year, with Adjusted Operating Income up 27%. The company executed significant agreements including India's 'one nation, one subscription' and a Brazil transformational agreement, expanding access to thousands of institutions. Research submissions increased 18% with output up 8%.
For FY2025, Wiley reaffirms outlook at mid-to-high end of ranges, projecting approximately 3% revenue growth and raising its FY2026 Adjusted EBITDA margin target to 25%+. The company's focus on scientific research and AI model development continues to drive growth, with notable expansion in open access, solutions, and AI licensing revenue.
Wiley (NYSE: WLY) ha riportato risultati solidi per il terzo trimestre del 2025, con notevoli miglioramenti nella redditività nonostante le sfide sui ricavi. I ricavi del terzo trimestre sono stati di 405 milioni di dollari, in calo rispetto ai 461 milioni a causa delle attività cedute, ma i ricavi rettificati sono cresciuti dell'1,2% a valuta costante. Il segmento Ricerca ha mostrato una performance robusta con una crescita del 5,2%.
Il reddito operativo del Q3 ha raggiunto i 52 milioni di dollari rispetto ai (-46 milioni) dell'anno precedente, con un aumento del 27% del reddito operativo rettificato. L'azienda ha stipulato accordi significativi, tra cui 'una nazione, un abbonamento' in India e un accordo trasformativo in Brasile, ampliando l'accesso a migliaia di istituzioni. Le sottomissioni di ricerca sono aumentate del 18% con un output in aumento dell'8%.
Per l'anno fiscale 2025, Wiley riafferma le previsioni nella parte medio-alta delle fasce, prevedendo una crescita dei ricavi di circa il 3% e alzando il suo obiettivo di margine EBITDA rettificato per il FY2026 al 25% o più. L'attenzione dell'azienda sulla ricerca scientifica e sullo sviluppo di modelli di intelligenza artificiale continua a guidare la crescita, con una notevole espansione nei ricavi da accesso aperto, soluzioni e licenze AI.
Wiley (NYSE: WLY) reportó resultados sólidos para el tercer trimestre de 2025, con notables mejoras en la rentabilidad a pesar de los desafíos en los ingresos. Los ingresos del tercer trimestre fueron de 405 millones de dólares, una disminución respecto a los 461 millones debido a negocios desinvertidos, pero los ingresos ajustados crecieron un 1.2% a moneda constante. El segmento de Investigación mostró un desempeño robusto con un crecimiento del 5.2%.
El ingreso operativo del Q3 alcanzó los 52 millones de dólares en comparación con (-46 millones) del año anterior, con un aumento del 27% en el ingreso operativo ajustado. La compañía ejecutó acuerdos significativos, incluyendo 'una nación, una suscripción' en India y un acuerdo transformador en Brasil, ampliando el acceso a miles de instituciones. Las presentaciones de investigación aumentaron un 18% con una producción en aumento del 8%.
Para el año fiscal 2025, Wiley reafirma su perspectiva en el extremo medio-alto de los rangos, proyectando un crecimiento de ingresos de aproximadamente el 3% y elevando su objetivo de margen EBITDA ajustado para el FY2026 al 25% o más. El enfoque de la empresa en la investigación científica y el desarrollo de modelos de IA sigue impulsando el crecimiento, con una notable expansión en los ingresos por acceso abierto, soluciones y licencias de IA.
와일리 (NYSE: WLY)는 2025년 3분기 실적을 발표하며 수익성에서 눈에 띄는 개선을 보였으나 매출에는 어려움이 있었습니다. 3분기 매출은 4억 5백만 달러로, 매각된 사업으로 인해 4억 6천 1백만 달러에서 감소했지만, 조정된 매출은 고정 환율 기준으로 1.2% 증가했습니다. 연구 부문은 5.2% 성장하며 강력한 성과를 보였습니다.
3분기 운영 수익은 5천 2백만 달러에 달하며, 전년 대비 (-4천 6백만 달러)에서 개선되었고, 조정된 운영 수익은 27% 증가했습니다. 회사는 '하나의 국가, 하나의 구독'이라는 인도의 중요한 계약과 브라질의 변혁적 계약을 체결하여 수천 개의 기관에 대한 접근을 확대했습니다. 연구 제출은 18% 증가했으며, 산출물은 8% 증가했습니다.
2025 회계연도에 대해 와일리는 예측을 중상위 범위에서 재확인하며 약 3%의 매출 성장을 예상하고 FY2026 조정 EBITDA 마진 목표를 25% 이상으로 상향 조정했습니다. 회사의 과학 연구 및 AI 모델 개발에 대한 집중은 성장을 계속 이끌고 있으며, 오픈 액세스, 솔루션 및 AI 라이센스 수익에서 눈에 띄는 확장이 이루어지고 있습니다.
Wiley (NYSE: WLY) a annoncé de solides résultats pour le troisième trimestre 2025, avec des améliorations notables de la rentabilité malgré des défis en matière de revenus. Les revenus du troisième trimestre se sont élevés à 405 millions de dollars, en baisse par rapport à 461 millions de dollars en raison des activités cédées, mais les revenus ajustés ont augmenté de 1,2 % à taux de change constant. Le secteur de la recherche a montré une performance robuste avec une croissance de 5,2 %.
Le résultat opérationnel du T3 a atteint 52 millions de dollars par rapport à (-46 millions) l'année précédente, avec une augmentation de 27 % du résultat opérationnel ajusté. L'entreprise a conclu des accords significatifs, notamment 'une nation, un abonnement' en Inde et un accord transformateur au Brésil, élargissant l'accès à des milliers d'institutions. Les soumissions de recherche ont augmenté de 18 % avec une production en hausse de 8 %.
Pour l'exercice 2025, Wiley réaffirme ses prévisions dans la partie moyenne à haute de la fourchette, projetant une croissance des revenus d'environ 3 % et relevant son objectif de marge EBITDA ajustée pour l'exercice 2026 à 25 % ou plus. L'accent mis par l'entreprise sur la recherche scientifique et le développement de modèles d'IA continue de stimuler la croissance, avec une expansion notable des revenus liés à l'accès ouvert, aux solutions et aux licences d'IA.
Wiley (NYSE: WLY) hat starke Ergebnisse für das dritte Quartal 2025 gemeldet, mit bemerkenswerten Verbesserungen der Rentabilität trotz Herausforderungen bei den Einnahmen. Der Umsatz im dritten Quartal betrug 405 Millionen Dollar, ein Rückgang von 461 Millionen Dollar aufgrund veräußerten Geschäftsbereichen, aber der bereinigte Umsatz wuchs um 1,2% bei konstanten Währungen. Das Forschungssegment zeigte eine robuste Leistung mit einem Wachstum von 5,2%.
Das Betriebsergebnis im Q3 erreichte 52 Millionen Dollar im Vergleich zu (-46 Millionen) im Vorjahr, wobei das bereinigte Betriebsergebnis um 27% stieg. Das Unternehmen hat bedeutende Vereinbarungen getroffen, darunter 'eine Nation, ein Abonnement' in Indien und eine transformative Vereinbarung in Brasilien, die den Zugang zu Tausenden von Institutionen erweitert. Die Forschungseinreichungen stiegen um 18%, während die Produktionsmenge um 8% zunahm.
Für das Geschäftsjahr 2025 bekräftigt Wiley die Aussichten im mittleren bis oberen Bereich der Spanne, mit einer Prognose von etwa 3% Umsatzwachstum und einer Erhöhung des Ziels für die bereinigte EBITDA-Marge für das Geschäftsjahr 2026 auf über 25%. Der Fokus des Unternehmens auf wissenschaftliche Forschung und die Entwicklung von KI-Modellen trägt weiterhin zum Wachstum bei, mit bemerkenswerter Expansion bei Open-Access-, Lösungs- und KI-Lizenzgebühren.
- Operating Income improved to $52M vs ($46M) loss prior year
- Research segment revenue up 5.2% with strong submissions growth of 18%
- Adjusted Operating Income increased 27% with margin up 280bps
- Secured major institutional agreements in India and Brazil
- Free Cash Flow improved by $44M year-over-year
- Raised FY2026 EBITDA margin target to 25%+
- Total revenue declined to $405M from $461M due to divested businesses
- Learning segment revenue down 6% with Academic segment declining 9%
- Q3 reported EPS remained negative at ($0.43)
- Net Debt-to-EBITDA ratio increased to 2.0 from 1.9 year-ago
Insights
Wiley's Q3 FY2025 results demonstrate significant margin expansion despite revenue pressures from divested businesses. While reported revenue declined to
The standout performer was the Research segment (
The Learning segment faced challenges, with revenue declining
Particularly noteworthy is Wiley's dramatically improved profitability metrics. Adjusted operating income increased
Management's confidence is evident in their guidance, reaffirming FY2025 outlook at the mid-to-high end of ranges and raising the FY2026 margin target to
The recurring revenue model in Research provides stability, while AI licensing represents an emerging growth driver, with two significant deals executed this quarter including a
Reaffirming Fiscal 2025 outlook at mid-to-high end of ranges from strong performance and profit improvement year-to-date; raising Fiscal 2026 margin target
-
Third quarter reported revenue of
vs.$405 million due to foregone revenue from divested businesses; Adjusted Revenue (excluding divestitures) +$461 million 1.2% at constant currency as expected; Research +5.2% constant currency -
Third quarter Operating Income
vs. ($52 million ); Adjusted Operating Income +$46 million 27% with margin up 280bps. Earnings Per Share (EPS) up to ($1.65 ); Adjusted EPS +$0.43 39% and Adjusted EBITDA +4% -
Year-to-date reported revenue of
vs.$1,235 million due to foregone revenue from divested businesses; Adjusted Revenue (excluding divestitures) +$1,405 million 3.5% at constant currency -
Year-to-date Operating Income of
vs. ($145 million ); Adjusted Operating Income +$17 million 38% with margin up 330 basis points. Earnings Per Share (EPS) of vs. ($0.29 ); Adjusted EPS +$4.10 43% , Adjusted EBITDA +12% , Cash from Operations +115% to and Free Cash Flow$52 million + $44 million
“We continue to deliver disciplined growth and material margin expansion as we capitalize on the global demand for scientific research and responsible AI model development,” said Matthew Kissner, Wiley President and CEO. “Our recurring revenue Research business has not only proven to be resilient across economic cycles but poised for continued expansion; our authoritative content and data-driven insights are increasingly coveted by corporations for their research and development initiatives, including AI enablement; and our strong execution and cost re-engineering efforts continue to deliver tangible results, with significant margin and cash flow improvement this year and raised margin expectations for Fiscal 2026.”
RESEARCH
-
Revenue of
was up$268 million 4% as reported and5% at constant currency driven by growth in open access, solutions, and AI licensing. During the quarter, Wiley executed two landmark recurring revenue agreements, includingIndia (“one nation, one subscription” expanding access to over 6,000 institutions) andBrazil (transformational agreement expanding access to over 430 institutions). Leading indicators remain strong year-to-date, with submissions up18% and output up8% . Wiley also expanded a previously executed content licensing project for training this quarter valued at . For the nine months, Research revenue was up$9 million 3% as reported and at constant currency. Excluding AI revenue, Research revenue rose2% in the quarter and year-to-date, both at constant currency. -
Adjusted EBITDA of
was up$88 million 11% as reported and12% at constant currency due to revenue growth. Adjusted EBITDA margin for the quarter rose to32.7% from30.9% in the prior year period. Year-to-date, Research Adjusted EBITDA margin was up 30 basis points to31.1% .
LEARNING
-
Revenue of
was down$137 million 6% as reported and at constant currency. Year-over-year results were impacted by a licensing renewal in the prior year and softness in Academic. At constant currency, Academic was down$6 million 9% in a seasonally small quarter and Professional was down1% . For the nine months, Learning revenue was up5% , or4% at constant currency driven by AI licensing. Excluding AI licensing revenue, Learning revenue declined0.6% year-to-date at constant currency. -
Adjusted EBITDA of
was down$49 million 5% as reported and at constant currency due to revenue performance. Adjusted EBITDA margin for the quarter rose to35.4% from35.1% in the prior year. Year-to-date, Learning Adjusted EBITDA margin was up over 400 basis points to35.3% .
CORPORATE EXPENSES
-
Corporate expenses declined by
due to lower depreciation and amortization but rose$3 million on an Adjusted EBITDA basis due to enterprise modernization and consulting fees related to strategic initiatives, including the re-engineering of our cost structure. Adjusted Corporate Expenses are the portion of shared services costs not allocated to segments.$3 million
EARNINGS PER SHARE
-
GAAP EPS was a loss of (
) compared to a loss of ($0.43 ) in the prior year period. The quarterly loss was primarily due to the previously disclosed non-cash income tax adjustment as a consequence of the US valuation allowance related to our divested businesses, a further loss on the sale of our Wiley Edge business, and restructuring charges. See the accompanying reconciliation table for more information.$2.08 -
Adjusted EPS of
was up$0.84 39% at constant currency due to higher adjusted operating income and a lower effective tax rate.
BALANCE SHEET, CASH FLOW, AND CAPITAL ALLOCATION (YTD)
- Net Debt-to-EBITDA Ratio (Trailing Twelve Months) was 2.0 compared to 1.9 in year-ago period.
-
Net Cash provided by Operating Activities was up
to$28 million mainly due to improved operating performance and timing of working capital.$52 million -
Free Cash Flow was up
to a use of$44 million , driven by improved operating performance, lower capex, and the timing of working capital. Free Cash Flow is typically a use through nine months due to timing.$1 million -
Returns to Shareholders: Wiley allocated
toward dividends and share repurchases, up from$93 million in the prior year.$87 million was allocated to share repurchases.$35 million
FISCAL 2025 OUTLOOK
Wiley is reaffirming its Fiscal 2025 growth outlook in the mid-to-high end of its ranges:
-
Revenue: middle of range, equating to top line growth of approximately
3% . Research and Learning are reaffirmed at low-to-mid single digit and low single digit growth, respectively - Adjusted EBITDA: middle of range, equating to high-single digit growth over prior year
-
Adjusted EBITDA margin: high end of range of 23
-24% - Adjusted EPS: high end of range, equating to strong double-digit growth over prior year
-
Free Cash Flow: reaffirmed at
, equating to growth of approximately$125 million 10% over prior year
Metric |
Fiscal 2024 Results |
Fiscal 2025 Outlook |
Q3 2025 Update |
Adj. Revenue* |
|
|
Middle of range |
Adj. EBITDA* Margin |
|
23 |
Middle of range High end of range |
Adj. EPS* |
|
|
High end of range |
Free Cash Flow |
|
Approx. |
Reaffirmed |
*Excludes held for sale or sold businesses. Wiley’s fiscal year runs from May 1 to April 30. Refer to our Annual Report on Form 10-K for the fiscal year ended April 30, 2024 for our Non-GAAP reconciliations to US GAAP results. |
FISCAL 2026 TARGETS
The Company is raising its Fiscal 2026 margin target and reaffirming its Fiscal 2026 revenue and cash flow targets. Wiley will disclose its full guidance for Fiscal 2026 in June 2025.
- Reaffirming low-to-mid single digit revenue growth
-
Raising Adjusted EBITDA Margin target to
25% + from a range of 24-25% -
Reaffirming Free Cash Flow of
$200 million
EARNINGS CONFERENCE CALL
Wiley will conduct a conference call with investors to discuss this earnings release today at 10:00 am (ET). You can access this via webcast at investors.wiley.com, or directly at https://events.q4inc.com/attendee/253283908.
ABOUT WILEY
Wiley (NYSE: WLY) is one of the world’s largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We enable knowledge-seekers to transform today’s biggest obstacles into tomorrow’s brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com and investors.wiley.com
*NON-GAAP FINANCIAL MEASURES
Wiley provides non-GAAP financial measures and performance results such as “Adjusted EPS,” “Adjusted Operating Income,” “Adjusted EBITDA,” “Adjusted Income before Taxes,” “Adjusted Income Tax Provision,” “Adjusted Effective Income Tax Rate,” “Free Cash Flow less Product Development Spending,” “organic revenue,” “Adjusted Revenue,” and results on a Constant Currency basis to assess underlying business performance and trends. Management believes non-GAAP financial measures, which exclude the impact of restructuring charges and credits and certain other items, and the impact of divestitures and acquisitions provide a useful comparable basis to analyze operating results and earnings. See the reconciliations of non-GAAP financial measures and explanations of the uses of non-GAAP measures in the supplementary information. We have not provided our 2025 outlook for the most directly comparable
FORWARD-LOOKING STATEMENTS
This release contains certain forward-looking statements concerning the Company's operations, performance, and financial condition. Reliance should not be placed on forward-looking statements, as actual results may differ materially from those in any forward-looking statements. Any such forward-looking statements are based upon a number of assumptions and estimates that are inherently subject to uncertainties and contingencies, many of which are beyond the control of the Company and are subject to change based on many important factors. Such factors include, but are not limited to: (i) the level of investment in new technologies and products; (ii) subscriber renewal rates for the Company's journals; (iii) the financial stability and liquidity of journal subscription agents; (iv) the consolidation of book wholesalers and retail accounts; (v) the market position and financial stability of key online retailers; (vi) the seasonal nature of the Company's educational business and the impact of the used book market; (vii) worldwide economic and political conditions; (viii) the Company's ability to protect its copyrights and other intellectual property worldwide (ix) the ability of the Company to successfully integrate acquired operations and realize expected opportunities; (x) the ability to realize operating savings over time and in fiscal year 2025 in connection with our multiyear Global Restructuring Program and planned and completed dispositions; (xi) cyber risk and the failure to maintain the integrity of our operational or security systems or infrastructure, or those of third parties with which we do business; (xii) as a result of acquisitions, we have and may record a significant amount of goodwill and other identifiable intangible assets and we may never realize the full carrying value of these assets; (xiii) our ability to leverage artificial intelligence technologies in our products and services, including generative artificial intelligence, large language models, machine learning, and other artificial intelligence tools; and (xiv) other factors detailed from time to time in our filings with the SEC. The Company undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
CATEGORY: EARNINGS RELEASES
JOHN WILEY & SONS, INC. | ||||||||||||||||
SUPPLEMENTARY INFORMATION (1)(2) | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF NET (LOSS) INCOME | ||||||||||||||||
(Dollars in thousands, except per share information) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
January 31, | January 31, | |||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
||
Revenue, net | $ |
404,626 |
|
$ |
460,705 |
|
$ |
1,235,030 |
|
$ |
1,404,526 |
|
||||
Costs and expenses: | ||||||||||||||||
Cost of sales |
|
104,219 |
|
|
143,662 |
|
|
320,439 |
|
|
456,377 |
|
||||
Operating and administrative expenses |
|
229,960 |
|
|
253,375 |
|
|
717,670 |
|
|
761,458 |
|
||||
Impairment of goodwill(3) |
|
- |
|
|
81,754 |
|
|
- |
|
|
108,449 |
|
||||
Restructuring and related charges |
|
5,574 |
|
|
14,808 |
|
|
13,071 |
|
|
52,033 |
|
||||
Amortization of intangible assets |
|
13,042 |
|
|
13,517 |
|
|
38,913 |
|
|
42,730 |
|
||||
Total costs and expenses |
|
352,795 |
|
|
507,116 |
|
|
1,090,093 |
|
|
1,421,047 |
|
||||
Operating income (loss) |
|
51,831 |
|
|
(46,411 |
) |
|
144,937 |
|
|
(16,521 |
) |
||||
As a % of revenue |
|
12.8 |
% |
|
-10.1 |
% |
|
11.7 |
% |
|
-1.2 |
% |
||||
Interest expense |
|
(14,027 |
) |
|
(13,321 |
) |
|
(41,277 |
) |
|
(37,592 |
) |
||||
Net foreign exchange transaction (losses) gains |
|
(4,222 |
) |
|
488 |
|
|
(7,316 |
) |
|
(3,489 |
) |
||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale(3) |
|
(15,930 |
) |
|
(52,404 |
) |
|
(9,760 |
) |
|
(179,747 |
) |
||||
Other income (expense), net |
|
1,021 |
|
|
(648 |
) |
|
4,029 |
|
|
(3,700 |
) |
||||
Income (loss) before taxes |
|
18,673 |
|
|
(112,296 |
) |
|
90,613 |
|
|
(241,049 |
) |
||||
Provision (benefit) for income taxes |
|
41,627 |
|
|
1,579 |
|
|
74,545 |
|
|
(15,465 |
) |
||||
Effective tax rate |
|
222.9 |
% |
|
-1.4 |
% |
|
82.3 |
% |
|
6.4 |
% |
||||
Net (loss) income | $ |
(22,954 |
) |
$ |
(113,875 |
) |
$ |
16,068 |
|
$ |
(225,584 |
) |
||||
As a % of revenue |
|
-5.7 |
% |
|
-24.7 |
% |
|
1.3 |
% |
|
-16.1 |
% |
||||
(Loss) earnings per share | ||||||||||||||||
Basic | $ |
(0.43 |
) |
$ |
(2.08 |
) |
$ |
0.30 |
|
$ |
(4.10 |
) |
||||
Diluted(4) | $ |
(0.43 |
) |
$ |
(2.08 |
) |
$ |
0.29 |
|
$ |
(4.10 |
) |
||||
Weighted average number of common shares outstanding | ||||||||||||||||
Basic |
|
53,952 |
|
|
54,812 |
|
|
54,173 |
|
|
55,061 |
|
||||
Diluted(4) |
|
53,952 |
|
|
54,812 |
|
|
54,815 |
|
|
55,061 |
|
||||
Notes: | ||||||||||||||||
(1) The supplementary information included in this press release for the three and nine months ended January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. | ||||||||||||||||
(2) All amounts are approximate due to rounding. | ||||||||||||||||
(3) Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale For the three and nine months ended January 31, 2025 and 2024, we recorded net pretax loss on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: |
||||||||||||||||
Three Months Ended January 31, |
Nine Months Ended January 31, |
|||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
||
Wiley Edge | $ |
(15,566 |
) |
$ |
(20,676 |
) |
$ |
(14,778 |
) |
$ |
(20,676 |
) |
||||
University Services |
|
(639 |
) |
|
(25,946 |
) |
|
850 |
|
|
(101,412 |
) |
||||
CrossKnowledge |
|
275 |
|
|
(5,782 |
) |
|
4,197 |
|
|
(56,159 |
) |
||||
Tuition Manager |
|
- |
|
|
- |
|
|
120 |
|
|
(1,500 |
) |
||||
Sale of assets |
|
- |
|
|
- |
|
|
(149 |
) |
|
- |
|
||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ |
(15,930 |
) |
$ |
(52,404 |
) |
$ |
(9,760 |
) |
$ |
(179,747 |
) |
||||
As previously announced in fiscal year 2024, we executed a plan to divest non-core businesses included in our Held for Sale or Sold segment, including University Services, Wiley Edge, and CrossKnowledge. These three businesses met the held-for-sale criteria starting in the first quarter of fiscal year 2024. We measured each disposal group at the lower of carrying value or fair value less costs to sell prior to its disposition. On January 1, 2024, we completed the sale of University Services. On May 31, 2024, we completed the sale of Wiley Edge, with the exception of its In the three months ended January 31, 2025, we recognized a net loss of In the second quarter of fiscal year 2025, we sold a facility which was reflected in Technology, property, and equipment, net in our Unaudited Condensed Consolidated Statements of Financial Position. Impairment of goodwill In fiscal year 2024, we reorganized our segments and recorded pretax noncash goodwill impairments of |
||||||||||||||||
(4) In calculating diluted net loss per common share for the three months ended January 31, 2025 and the three and nine months ended January 31, 2024, our diluted weighted average number of common shares outstanding excludes the effect of unvested restricted stock units and other stock awards as the effect was antidilutive. This occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. |
JOHN WILEY & SONS, INC. | |||||||||||||||||
SUPPLEMENTARY INFORMATION (1) (2) | |||||||||||||||||
RECONCILIATION OF US GAAP MEASURES to NON-GAAP MEASURES | |||||||||||||||||
(unaudited) | |||||||||||||||||
Reconciliation of US GAAP (Loss) Earnings per Share to Non-GAAP Adjusted EPS | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
January 31, | January 31, | ||||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|||
US GAAP (Loss) Earnings Per Share - Diluted | $ |
(0.43 |
) |
$ |
(2.08 |
) |
$ |
0.29 |
|
$ |
(4.10 |
) |
|||||
Adjustments: | |||||||||||||||||
Impairment of goodwill |
|
- |
|
|
1.48 |
|
|
- |
|
|
1.90 |
|
|||||
Restructuring and related charges |
|
0.09 |
|
|
0.20 |
|
|
0.21 |
|
|
0.70 |
|
|||||
Foreign exchange losses (gains) on intercompany transactions, including the write off of certain cumulative translation adjustments (3) |
|
0.09 |
|
|
(0.03 |
) |
|
0.09 |
|
|
0.02 |
|
|||||
Amortization of acquired intangible assets (4) |
|
0.20 |
|
|
0.22 |
|
|
0.62 |
|
|
0.65 |
|
|||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) |
|
0.29 |
|
|
0.83 |
|
|
0.20 |
|
|
2.77 |
|
|||||
Held for Sale or Sold segment Adjusted Net (Income) Loss (5) |
|
- |
|
|
(0.05 |
) |
|
0.05 |
|
|
(0.39 |
) |
|||||
Income tax adjustments |
|
0.58 |
|
|
- |
|
|
0.82 |
|
|
- |
|
|||||
EPS impact of using weighted-average dilutive shares for adjusted EPS calculation (6) |
|
0.02 |
|
|
0.02 |
|
|
- |
|
|
0.04 |
|
|||||
Non-GAAP Adjusted Earnings Per Share - Diluted | $ |
0.84 |
|
$ |
0.59 |
|
$ |
2.28 |
|
$ |
1.59 |
|
|||||
Reconciliation of US GAAP Income (Loss) Before Taxes to Non-GAAP Adjusted Income Before Taxes | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
(amounts in thousands) | January 31, | January 31, | |||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|||
US GAAP Income (Loss) Before Taxes | $ |
18,673 |
|
$ |
(112,296 |
) |
$ |
90,613 |
|
$ |
(241,049 |
) |
|||||
Pretax Impact of Adjustments: | |||||||||||||||||
Impairment of goodwill |
|
- |
|
|
81,754 |
|
|
- |
|
|
108,449 |
|
|||||
Restructuring and related charges |
|
5,574 |
|
|
14,808 |
|
|
13,071 |
|
|
52,033 |
|
|||||
Foreign exchange losses (gains) on intercompany transactions, including the write off of certain cumulative translation adjustments (3) |
|
5,239 |
|
|
(2,128 |
) |
|
5,590 |
|
|
1,089 |
|
|||||
Amortization of acquired intangible assets (4) |
|
13,042 |
|
|
13,580 |
|
|
38,956 |
|
|
44,550 |
|
|||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) |
|
15,930 |
|
|
52,404 |
|
|
9,760 |
|
|
179,747 |
|
|||||
Held for Sale or Sold segment Adjusted (Income) Loss Before Taxes (5) |
|
- |
|
|
(4,120 |
) |
|
3,578 |
|
|
(28,253 |
) |
|||||
Non-GAAP Adjusted Income Before Taxes | $ |
58,458 |
|
$ |
44,002 |
|
$ |
161,568 |
|
$ |
116,566 |
|
|||||
Reconciliation of US GAAP Income Tax Provision (Benefit) to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate | |||||||||||||||||
US GAAP Income Tax Provision (Benefit) | $ |
41,627 |
|
$ |
1,579 |
|
$ |
74,545 |
|
$ |
(15,465 |
) |
|||||
Income Tax Impact of Adjustments (7) | |||||||||||||||||
Impairment of goodwill |
|
- |
|
|
- |
|
|
- |
|
|
2,697 |
|
|||||
Restructuring and related charges |
|
404 |
|
|
3,985 |
|
|
1,315 |
|
|
13,237 |
|
|||||
Foreign exchange losses (gains) on intercompany transactions, including the write off of certain cumulative translation adjustments (3) |
|
260 |
|
|
(742 |
) |
|
599 |
|
|
112 |
|
|||||
Amortization of acquired intangible assets (4) |
|
1,910 |
|
|
1,152 |
|
|
5,511 |
|
|
8,668 |
|
|||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) |
|
154 |
|
|
6,508 |
|
|
(1,360 |
) |
|
25,711 |
|
|||||
Held for Sale or Sold segment Adjusted Tax (Provision) Benefit (5) |
|
- |
|
|
(1,252 |
) |
|
887 |
|
|
(6,518 |
) |
|||||
Income Tax Adjustments | |||||||||||||||||
Impact of valuation allowance on the US GAAP effective tax rate (8) |
|
(31,744 |
) |
|
- |
|
|
(44,863 |
) |
|
- |
|
|||||
Non-GAAP Adjusted Income Tax Provision | $ |
12,611 |
|
$ |
11,230 |
|
$ |
36,634 |
|
$ |
28,442 |
|
|||||
US GAAP Effective Tax Rate |
|
222.9 |
% |
|
-1.4 |
% |
|
82.3 |
% |
|
6.4 |
% |
|||||
Non-GAAP Adjusted Effective Tax Rate |
|
21.6 |
% |
|
25.5 |
% |
|
22.7 |
% |
|
24.4 |
% |
|||||
Notes: | |||||||||||||||||
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three and nine months ended January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. | |||||||||||||||||
(2) All amounts are approximate due to rounding. | |||||||||||||||||
(3) In fiscal year 2023 due to the closure of our operations in |
|||||||||||||||||
(4) Reflects the amortization of intangible assets established on the opening balance sheet for an acquired business. This includes the amortization of intangible assets such as developed technology, customer relationships, tradenames, etc., which is reflected in the "Amortization of intangible assets" line in the Condensed Consolidated Statements of Net (Loss) Income. It also includes the amortization of acquired product development assets, which is reflected in Cost of sales in the Condensed Consolidated Statements of Net (Loss) Income. | |||||||||||||||||
(5) For the three and nine months ended January 31, 2025 and 2024, we recorded net pretax loss on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: | |||||||||||||||||
Three Months Ended January 31, |
Nine Months Ended January 31, |
||||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|||
Wiley Edge | $ |
15,566 |
|
$ |
20,676 |
|
$ |
14,778 |
|
$ |
20,676 |
|
|||||
University Services |
|
639 |
|
|
25,946 |
|
|
(850 |
) |
|
101,412 |
|
|||||
CrossKnowledge |
|
(275 |
) |
|
5,782 |
|
|
(4,197 |
) |
|
56,159 |
|
|||||
Tuition Manager |
|
- |
|
|
- |
|
|
(120 |
) |
|
1,500 |
|
|||||
Sale of assets |
|
- |
|
|
- |
|
|
149 |
|
|
- |
|
|||||
Net pretax loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ |
15,930 |
|
$ |
52,404 |
|
$ |
9,760 |
|
$ |
179,747 |
|
|||||
For the three and nine months ended January 31, 2025 and 2024, we recorded income tax benefit (provision) on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: | |||||||||||||||||
Three Months Ended January 31, |
Nine Months Ended January 31, |
||||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|||
Wiley Edge | $ |
154 |
|
$ |
- |
|
$ |
(1,330 |
) |
$ |
- |
|
|||||
University Services |
|
- |
|
|
6,508 |
|
|
- |
|
|
25,337 |
|
|||||
CrossKnowledge |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|||||
Tuition Manager |
|
- |
|
|
- |
|
|
(30 |
) |
|
374 |
|
|||||
Sale of assets |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|||||
Benefit (provision) on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ |
154 |
|
$ |
6,508 |
|
$ |
(1,360 |
) |
$ |
25,711 |
|
|||||
In addition, our Adjusted EPS excludes the Adjusted Net Income or Loss of our Held for Sale or Sold segment. | |||||||||||||||||
(6) Represents the impact of using diluted weighted-average number of common shares outstanding (54.6 million shares for the three months ended January 31, 2025 and 55.3 million and 55.6 million shares for the three and nine months ended January 31, 2024, respectively) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. | |||||||||||||||||
(7) For the three and nine months ended January 31, 2025 and 2024, substantially all of the tax impact was from deferred taxes. | |||||||||||||||||
(8) In the nine months ended January 31, 2025, there was an impact on the US GAAP effective tax rate due to the valuation allowance on deferred tax assets in the US of |
JOHN WILEY & SONS, INC. | ||||||||||||||||
SUPPLEMENTARY INFORMATION (1) | ||||||||||||||||
RECONCILIATION OF US GAAP NET (LOSS) INCOME TO NON-GAAP EBITDA AND ADJUSTED EBITDA | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
January 31, | January 31, | |||||||||||||||
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
||
Net (Loss) Income | $ |
(22,954 |
) |
$ |
(113,875 |
) |
$ |
16,068 |
|
$ |
(225,584 |
) |
||||
Interest expense |
|
14,027 |
|
|
13,321 |
|
|
41,277 |
|
|
37,592 |
|
||||
Provision (benefit) for income taxes |
|
41,627 |
|
|
1,579 |
|
|
74,545 |
|
|
(15,465 |
) |
||||
Depreciation and amortization |
|
36,474 |
|
|
45,474 |
|
|
110,445 |
|
|
129,376 |
|
||||
Non-GAAP EBITDA |
|
69,174 |
|
|
(53,501 |
) |
|
242,335 |
|
|
(74,081 |
) |
||||
Impairment of goodwill |
|
- |
|
|
81,754 |
|
|
- |
|
|
108,449 |
|
||||
Restructuring and related charges |
|
5,574 |
|
|
14,808 |
|
|
13,071 |
|
|
52,033 |
|
||||
Net foreign exchange transaction losses (gains) |
|
4,222 |
|
|
(488 |
) |
|
7,316 |
|
|
3,489 |
|
||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale |
|
15,930 |
|
|
52,404 |
|
|
9,760 |
|
|
179,747 |
|
||||
Other (income) expense, net |
|
(1,021 |
) |
|
648 |
|
|
(4,029 |
) |
|
3,700 |
|
||||
Held for Sale or Sold segment Adjusted EBITDA (2) |
|
- |
|
|
(4,118 |
) |
|
3,578 |
|
|
(29,739 |
) |
||||
Non-GAAP Adjusted EBITDA | $ |
93,879 |
|
$ |
91,507 |
|
$ |
272,031 |
|
$ |
243,598 |
|
||||
Adjusted EBITDA Margin |
|
23.2 |
% |
|
22.7 |
% |
|
22.3 |
% |
|
20.7 |
% |
||||
Notes: | ||||||||||||||||
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three and nine months ended January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. | ||||||||||||||||
(2) Our Non-GAAP Adjusted EBITDA excludes the Held for Sale or Sold segment Non-GAAP Adjusted EBITDA. |
JOHN WILEY & SONS, INC. | |||||||||||
SUPPLEMENTARY INFORMATION (1) (2) | |||||||||||
SEGMENT RESULTS | |||||||||||
(in thousands) | |||||||||||
(unaudited) | |||||||||||
% Change | |||||||||||
Three Months Ended January 31, |
Favorable (Unfavorable) | ||||||||||
2025 |
|
2024 |
|
Reported | Constant Currency |
||||||
Research: | |||||||||||
Revenue, net | |||||||||||
Research Publishing | $ |
225,874 |
|
$ |
216,586 |
|
|
|
|||
Research Solutions |
|
41,670 |
|
|
39,613 |
|
|
|
|||
Total Revenue, net | $ |
267,544 |
|
$ |
256,199 |
|
|
|
|||
|
|
|
|||||||||
Non-GAAP Adjusted Operating Income | $ |
65,669 |
|
$ |
57,098 |
|
|
|
|||
Depreciation and amortization |
|
21,918 |
|
|
22,029 |
|
|
|
|||
Non-GAAP Adjusted EBITDA | $ |
87,587 |
|
$ |
79,127 |
|
|
|
|||
Adjusted EBITDA margin |
|
32.7 | % |
|
30.9 |
% |
|
|
|||
|
|
|
|||||||||
Learning: |
|
|
|
||||||||
Revenue, net |
|
|
|
||||||||
Academic | $ |
78,795 |
|
$ |
87,216 |
|
- |
- |
|||
Professional |
|
58,287 |
|
|
59,118 |
|
- |
- |
|||
Total Revenue, net | $ |
137,082 |
|
$ |
146,334 |
|
- |
- |
|||
|
|
|
|||||||||
Non-GAAP Adjusted Operating Income | $ |
37,764 |
|
$ |
37,513 |
|
|
|
|||
Depreciation and amortization |
|
10,761 |
|
|
13,812 |
|
|
|
|||
Non-GAAP Adjusted EBITDA | $ |
48,525 |
|
$ |
51,325 |
|
- |
- |
|||
Adjusted EBITDA margin |
|
35.4 | % |
|
35.1 |
% |
|
|
|||
|
|
|
|||||||||
Held for Sale or Sold: |
|
|
|
||||||||
Total Revenue, net | $ |
- |
|
$ |
58,172 |
|
# |
# |
|||
|
|
|
|||||||||
Non-GAAP Adjusted Operating Income | $ |
- |
|
$ |
4,118 |
|
# |
# |
|||
Depreciation and amortization |
|
- |
|
|
- |
|
# |
# |
|||
Non-GAAP Adjusted EBITDA | $ |
- |
|
$ |
4,118 |
|
# |
# |
|||
Adjusted EBITDA margin |
|
0.0 | % |
|
7.1 |
% |
|
|
|||
|
|
|
|||||||||
Corporate Expenses: |
|
|
|
||||||||
Non-GAAP Adjusted Corporate Expenses | $ |
(46,028 |
) |
$ |
(48,578 |
) |
|
|
|||
Depreciation and amortization |
|
3,795 |
|
|
9,633 |
|
|
|
|||
Non-GAAP Adjusted EBITDA | $ |
(42,233 |
) |
$ |
(38,945 |
) |
- |
- |
|||
|
|
||||||||||
Consolidated Results: |
|
|
|||||||||
Revenue, net | $ |
404,626 |
|
$ |
460,705 |
|
- |
- |
|||
Less: Held for Sale or Sold Segment (3) |
|
- |
|
|
(58,172 |
) |
# |
# |
|||
Adjusted Revenue, net | $ |
404,626 |
|
$ |
402,533 |
|
|
|
|||
|
|
|
|||||||||
Operating Income (Loss) | $ |
51,831 |
|
$ |
(46,411 |
) |
# |
# |
|||
Adjustments: |
|
|
|
||||||||
Restructuring charges |
|
5,574 |
|
|
14,808 |
|
|
|
|||
Impairment of goodwill |
|
- |
|
|
81,754 |
|
# |
# |
|||
Held for Sale or Sold Segment Adjusted Operating Income (3) |
|
- |
|
|
(4,118 |
) |
# |
# |
|||
Non-GAAP Adjusted Operating Income | $ |
57,405 |
|
$ |
46,033 |
|
|
|
|||
Adjusted Operating Income margin |
|
14.2 | % |
|
11.4 |
% |
|
|
|||
Depreciation and amortization |
|
36,474 |
|
|
45,474 |
|
|
|
|||
Less: Held for Sale or Sold Segment depreciation and amortization (3) |
|
- |
|
|
- |
|
# |
# |
|||
Non-GAAP Adjusted EBITDA | $ |
93,879 |
|
$ |
91,507 |
|
|
|
|||
Adjusted EBITDA margin | 23.2 | % |
|
22.7 |
% |
||||||
Notes: | |||||||||||
(1) The supplementary information included in this press release for the three and nine months ended January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. | |||||||||||
(2) All amounts are approximate due to rounding. | |||||||||||
(3) Our Adjusted Revenue, Adjusted Operating Income and Adjusted EBITDA excludes the impact of our Held for Sale or Sold segment Revenue, Adjusted Operating Income or Loss and Adjusted EBITDA results. | |||||||||||
#Variance greater than |
|||||||||||
JOHN WILEY & SONS, INC. | |||||||||||
SUPPLEMENTARY INFORMATION (1) (2) | |||||||||||
SEGMENT RESULTS | |||||||||||
(in thousands) | |||||||||||
(unaudited) | |||||||||||
% Change | |||||||||||
Nine Months Ended January 31, |
Favorable (Unfavorable) | ||||||||||
2025 |
|
|
2024 |
|
Reported | Constant Currency |
|||||
Research: | |||||||||||
Revenue, net | |||||||||||
Research Publishing | $ |
679,492 |
|
$ |
659,329 |
|
|
|
|||
Research Solutions |
|
115,246 |
|
|
112,344 |
|
|
|
|||
Total Revenue, net | $ |
794,738 |
|
$ |
771,673 |
|
|
|
|||
|
|||||||||||
Non-GAAP Adjusted Operating Income | $ |
180,412 |
|
$ |
169,481 |
|
|
|
|||
Depreciation and amortization |
|
66,999 |
|
|
67,909 |
|
|
|
|||
Non-GAAP Adjusted EBITDA | $ |
247,411 |
|
$ |
237,390 |
|
|
|
|||
Adjusted EBITDA margin | 31.1 |
% |
|
30.8 |
% |
||||||
Learning: | |||||||||||
Revenue, net | |||||||||||
Academic | $ |
233,547 |
|
$ |
224,633 |
|
|
|
|||
Professional |
|
189,363 |
|
|
179,961 |
|
|
|
|||
Total Revenue, net | $ |
422,910 |
|
$ |
404,594 |
|
|
|
|||
|
|||||||||||
Non-GAAP Adjusted Operating Income | $ |
116,135 |
|
$ |
85,051 |
|
|
|
|||
Depreciation and amortization |
|
32,952 |
|
|
41,338 |
|
|
|
|||
Non-GAAP Adjusted EBITDA | $ |
149,087 |
|
$ |
126,389 |
|
|
|
|||
Adjusted EBITDA margin |
|
35.3 |
% |
|
31.2 |
% |
|||||
|
|||||||||||
Held for Sale or Sold: |
|
||||||||||
Total Revenue, net | $ |
17,382 |
|
$ |
228,259 |
|
- |
- |
|||
Non-GAAP Adjusted Operating (Loss) Income | $ |
(3,578 |
) |
$ |
26,302 |
|
# |
# |
|||
Depreciation and amortization | - |
|
|
3,437 |
|
# |
# |
||||
Non-GAAP Adjusted EBITDA | $ |
(3,578 |
) |
$ |
29,739 |
|
# |
# |
|||
Adjusted EBITDA margin | -20.6 |
% |
|
13.0 |
% |
||||||
Corporate Expenses: | |||||||||||
Non-GAAP Adjusted Corporate Expenses | $ |
(134,961 |
) |
$ |
(136,873 |
) |
|
|
|||
Depreciation and amortization | 10,494 |
|
|
16,692 |
|
|
|
||||
Non-GAAP Adjusted EBITDA | $ |
(124,467 |
) |
$ |
(120,181 |
) |
- |
- |
|||
Consolidated Results: | |||||||||||
Revenue, net | $ |
1,235,030 |
|
$ |
1,404,526 |
|
- |
- |
|||
Less: Held for Sale or Sold Segment (3) |
|
(17,382 |
) |
|
(228,259 |
) |
- |
- |
|||
Adjusted Revenue, net | $ |
1,217,648 |
|
$ |
1,176,267 |
|
|
|
|||
|
|||||||||||
Operating Income (Loss) | $ |
144,937 |
|
$ |
(16,521 |
) |
# |
# |
|||
Adjustments: |
|
||||||||||
Restructuring charges |
|
13,071 |
|
|
52,033 |
|
|
|
|||
Impairment of goodwill |
|
- |
|
|
108,449 |
|
# |
# |
|||
Held for Sale or Sold Segment Adjusted Operating Loss (Income) (3) |
|
3,578 |
|
|
(26,302 |
) |
# |
# |
|||
Non-GAAP Adjusted Operating Income | $ |
161,586 |
|
$ |
117,659 |
|
|
|
|||
Adjusted Operating Income margin |
|
13.3 |
% |
|
10.0 |
% |
|||||
Depreciation and amortization |
|
110,445 |
|
|
129,376 |
|
|
|
|||
Less: Held for Sale or Sold depreciation and amortization (3) |
|
- |
|
|
(3,437 |
) |
# |
# |
|||
Non-GAAP Adjusted EBITDA | $ |
272,031 |
|
$ |
243,598 |
|
|
|
|||
Adjusted EBITDA margin | 22.3 |
% |
|
20.7 |
% |
||||||
#Variance greater than |
JOHN WILEY & SONS, INC. | ||||||
SUPPLEMENTARY INFORMATION (1) | ||||||
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | ||||||
(in thousands) | ||||||
(unaudited) | ||||||
January 31, | April 30, | |||||
2025 |
2024 |
|||||
Assets: | ||||||
Current assets | ||||||
Cash and cash equivalents | $ |
104,510 |
$ |
83,249 |
||
Accounts receivable, net |
|
184,672 |
|
224,198 |
||
Inventories, net |
|
25,305 |
|
26,219 |
||
Prepaid expenses and other current assets |
|
80,277 |
|
85,954 |
||
Current assets held-for-sale |
|
- |
|
34,422 |
||
Total current assets |
|
394,764 |
|
454,042 |
||
Technology, property and equipment, net |
|
164,502 |
|
192,438 |
||
Intangible assets, net |
|
572,123 |
|
615,694 |
||
Goodwill |
|
1,079,175 |
|
1,091,368 |
||
Operating lease right-of-use assets |
|
66,947 |
|
69,074 |
||
Other non-current assets |
|
322,341 |
|
283,719 |
||
Non-current assets held-for-sale |
|
- |
|
19,160 |
||
Total assets | $ |
2,599,852 |
$ |
2,725,495 |
||
Liabilities and shareholders' equity: | ||||||
Current liabilities | ||||||
Accounts payable | $ |
53,220 |
$ |
55,659 |
||
Accrued royalties |
|
156,271 |
|
97,173 |
||
Short-term portion of long-term debt |
|
10,000 |
|
7,500 |
||
Contract liabilities |
|
313,278 |
|
483,778 |
||
Accrued employment costs |
|
74,307 |
|
96,980 |
||
Short-term portion of operating lease liabilities |
|
17,969 |
|
18,294 |
||
Other accrued liabilities |
|
92,213 |
|
76,266 |
||
Current liabilities held-for-sale |
|
- |
|
37,632 |
||
Total current liabilities |
|
717,258 |
|
873,282 |
||
Long-term debt |
|
877,205 |
|
767,096 |
||
Accrued pension liability |
|
69,647 |
|
70,832 |
||
Deferred income tax liabilities |
|
94,567 |
|
97,186 |
||
Operating lease liabilities |
|
83,602 |
|
94,386 |
||
Other long-term liabilities |
|
72,329 |
|
71,760 |
||
Long-term liabilities held-for-sale |
|
- |
|
11,237 |
||
Total liabilities |
|
1,914,608 |
|
1,985,779 |
||
Shareholders' equity |
|
685,244 |
|
739,716 |
||
Total liabilities and shareholders' equity | $ |
2,599,852 |
$ |
2,725,495 |
||
Notes: | ||||||
(1) The supplementary information included in this press release for January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. |
JOHN WILEY & SONS, INC. | ||||||||
SUPPLEMENTARY INFORMATION (1) | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(in thousands) | ||||||||
(unaudited) | ||||||||
Nine Months Ended | ||||||||
January 31, | ||||||||
|
2025 |
|
|
2024 |
|
|||
Operating activities: | ||||||||
Net income (loss) | $ |
16,068 |
|
$ |
(225,584 |
) |
||
Impairment of goodwill |
|
- |
|
|
108,449 |
|
||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale |
|
9,760 |
|
|
179,747 |
|
||
Amortization of intangible assets |
|
38,913 |
|
|
42,730 |
|
||
Amortization of product development assets |
|
12,669 |
|
|
17,894 |
|
||
Depreciation and amortization of technology, property, and equipment |
|
58,863 |
|
|
68,752 |
|
||
Other noncash charges |
|
67,268 |
|
|
50,146 |
|
||
Net change in operating assets and liabilities |
|
(151,291 |
) |
|
(217,782 |
) |
||
Net cash provided by operating activities |
|
52,250 |
|
|
24,352 |
|
||
Investing activities: | ||||||||
Additions to technology, property, and equipment |
|
(42,347 |
) |
|
(57,275 |
) |
||
Product development spending |
|
(11,054 |
) |
|
(12,324 |
) |
||
Businesses acquired in purchase transactions, net of cash acquired |
|
(915 |
) |
|
(3,116 |
) |
||
Net cash transferred related to the sale of businesses and assets |
|
(11,239 |
) |
|
(1,237 |
) |
||
Acquisitions of publication rights and other |
|
(4,139 |
) |
|
(4,541 |
) |
||
Net cash used in investing activities |
|
(69,694 |
) |
|
(78,493 |
) |
||
Financing activities: | ||||||||
Net debt borrowings |
|
114,319 |
|
|
158,681 |
|
||
Cash dividends |
|
(57,243 |
) |
|
(57,869 |
) |
||
Purchases of treasury shares |
|
(35,421 |
) |
|
(29,000 |
) |
||
Other |
|
2,421 |
|
|
(16,458 |
) |
||
Net cash provided by financing activities |
|
24,076 |
|
|
55,354 |
|
||
Effects of exchange rate changes on cash, cash equivalents and restricted cash |
|
(1,615 |
) |
|
432 |
|
||
Change in cash, cash equivalents and restricted cash for period |
|
5,017 |
|
|
1,645 |
|
||
Cash, cash equivalents and restricted cash - beginning |
|
99,543 |
|
|
107,262 |
|
||
Cash, cash equivalents and restricted cash - ending | $ |
104,560 |
|
$ |
108,907 |
|
||
CALCULATION OF NON-GAAP FREE CASH FLOW LESS PRODUCT DEVELOPMENT SPENDING (2) | ||||||||
Nine Months Ended | ||||||||
January 31, | ||||||||
|
2025 |
|
|
2024 |
|
|||
Net cash provided by operating activities | $ |
52,250 |
|
$ |
24,352 |
|
||
Less: Additions to technology, property, and equipment |
|
(42,347 |
) |
|
(57,275 |
) |
||
Less: Product development spending |
|
(11,054 |
) |
|
(12,324 |
) |
||
Free cash flow less product development spending | $ |
(1,151 |
) |
$ |
(45,247 |
) |
||
Notes: | ||||||||
(1) The supplementary information included in this press release for the nine months ended January 31, 2025 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. | ||||||||
(2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplemental information. |
JOHN WILEY & SONS, INC.
EXPLANATION OF USAGE OF NON-GAAP PERFORMANCE MEASURES
In this earnings release and supplemental information, management may present the following non-GAAP performance measures:
- Adjusted Earnings Per Share (Adjusted EPS);
- Free Cash Flow less Product Development Spending;
- Adjusted Revenue;
- Adjusted Operating Income and margin;
- Adjusted Income Before Taxes;
- Adjusted Income Tax Provision;
- Adjusted Effective Tax Rate;
- EBITDA, Adjusted EBITDA and margin;
- Organic revenue; and
- Results on a constant currency basis.
Management uses these non-GAAP performance measures as supplemental indicators of our operating performance and financial position as well as for internal reporting and forecasting purposes, when publicly providing our outlook, to evaluate our performance and calculate incentive compensation.
We present these non-GAAP performance measures in addition to US GAAP financial results because we believe that these non-GAAP performance measures provide useful information to certain investors and financial analysts for operational trends and comparisons over time. The use of these non-GAAP performance measures may also provide a consistent basis to evaluate operating profitability and performance trends by excluding items that we do not consider to be controllable activities for this purpose.
The performance metric used by our chief operating decision maker to evaluate performance of our reportable segments is Adjusted Operating Income. We present both Adjusted Operating Income and Adjusted EBITDA for each of our reportable segments as we believe Adjusted EBITDA provides additional useful information to certain investors and financial analysts for operational trends and comparisons over time. It removes the impact of depreciation and amortization expense, as well as presents a consistent basis to evaluate operating profitability and compare our financial performance to that of our peer companies and competitors.
For example:
- Adjusted EPS, Adjusted Revenue, Adjusted Operating Income, Adjusted Income Before Taxes, Adjusted Income Tax Provision, Adjusted Effective Tax Rate, Adjusted EBITDA, and organic revenue (excluding acquisitions) provide a more comparable basis to analyze operating results and earnings and are measures commonly used by shareholders to measure our performance.
- Free Cash Flow less Product Development Spending helps assess our ability, over the long term, to create value for our shareholders as it represents cash available to repay debt, pay common stock dividends, and fund share repurchases and acquisitions.
- Results on a constant currency basis remove distortion from the effects of foreign currency movements to provide better comparability of our business trends from period to period. We measure our performance excluding the impact of foreign currency (or at constant currency), which means that we apply the same foreign currency exchange rates for the current and equivalent prior period.
In addition, we have historically provided these or similar non-GAAP performance measures and understand that some investors and financial analysts find this information helpful in analyzing our operating margins and net income, and in comparing our financial performance to that of our peer companies and competitors. Based on interactions with investors, we also believe that our non-GAAP performance measures are regarded as useful to our investors as supplemental to our US GAAP financial results, and that there is no confusion regarding the adjustments or our operating performance to our investors due to the comprehensive nature of our disclosures.
We have not provided our 2025 outlook for the most directly comparable US GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with US GAAP.
Non-GAAP performance measures do not have standardized meanings prescribed by US GAAP and therefore may not be comparable to the calculation of similar measures used by other companies and should not be viewed as alternatives to measures of financial results under US GAAP. The adjusted metrics have limitations as analytical tools, and should not be considered in isolation from, or as a substitute for, US GAAP information. It does not purport to represent any similarly titled US GAAP information and is not an indicator of our performance under US GAAP. Non-GAAP financial metrics that we present may not be comparable with similarly titled measures used by others. Investors are cautioned against placing undue reliance on these non-GAAP measures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306894570/en/
Media contact:
Andrea Sherman
asherman@wiley.com
(203) 536-7564
Source: John Wiley and Sons